What is the latest guidance on mpox (monkeypox) in 2025 in the EU?

Mpox (formerly called monkeypox) remains a monitored viral infection in Europe. In this episode, we explain current symptoms, transmission patterns, treatment options, and how telemedical care is handled under EU public health guidance.

In this episode, we cover:

• What mpox is (a viral infection caused by the monkeypox virus)

• How transmission occurs (close physical contact, skin lesions, respiratory droplets)

• Early symptoms: fever, swollen lymph nodes, fatigue

• Characteristic rash progression and lesion distribution

• Isolation recommendations under European health guidance

• When antiviral treatment (e.g., tecovirimat) may be considered

• Vaccination strategies for high-risk groups

• When hospital care is required (severe pain, secondary infection, complications)

• Situations where remote-only management may not be appropriate

Doctors assess travel history, exposure risk, lesion appearance, immune status, and symptom severity before advising management. Laboratory confirmation may be required. Severe symptoms, eye involvement, or immunocompromised patients require in-person evaluation.

This episode reflects how infectious disease concerns are reviewed within structured medical assessment in European telemedicine at Mobi Doctor.

Read the full medical guide here:

https://www.mobidoctor.eu/blog/mpox-monkeypox-in-2025-signs-treatment-telemedical-care-in-the-eu